Dr Meyer on the FDA Approval of Orca-T for HSCT in Hematologic Malignancies

The approval of Orca-T is really exciting, because it is the first approved T regulatory cell product in any indication, and it could herald a whole new generation of therapies that really use the immune system in a much more sophisticated way, based on the fact that we know what different cell populations do.

Everett Meyer, MD, PhD, an associate professor of medicine (blood & marrow transplantation), an associate professor of pediatrics (stem cell transplantation), and an associate professor of surgery (abdominal transplantation) at Stanford Medicine, discussed the significance of the FDA approval of allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi; Orca-T) for patients with hematologic malignancies.

On June 30, 2026, the FDA approved Orca-T for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-vs-host disease (cGHVD)–free survival(cGFS), in the treatment of adults with hematological malignancies.

The approval was backed by data from the phase 3 Precision-T trial (NCT05316701), which evaluated Orca-T (n = 93) followed by single-agent GVHD prophylaxis with tacrolimus, or unmanipulated allograft (n=94) followed by GVHD prophylaxis with tacrolimus and methotrexate. At a median follow-up of 8.48 months (range, 0-22) for the Orca-T arm and 9.03 months (range, 0-20) for the control arm, adult patients with acute leukemias or myelodysplastic syndromes who received Orca-T experienced a median cGFS that was not estimable (NE; 95% CI, NE-NE) vs 7.3 months (95% CI, 6.3-15.5) months for patients treated with unmanipulated allograft (HR, 0.26; 95% CI, 0.14-0.47; P < .00001).

Meyer explained that Orca-T serves a key advancement in the field, representing a more sophisticated way of leveraging the immune system for patients with hematologic malignancies with improved knowledge of the role of individual cell populations. Compared with conventional HSCT approaches, Orca-T allows clinicians to more safely and effectively treat patients, Meyer said.

A key benefit of Orca-T is the centralized manufacturing done by Orca Bio—the developer of Orca-T—which allows them to take donor apheresis and produce the final product for delivery to any center in the United States within 72 hours. These types of efforts underscore what the medical field and industry can accomplish when working in tandem, Meyer concluded.